Jan Schmollinger

Jan Schmollinger is a highly experienced scientist specializing in in vivo pharmacology and cancer immunotherapy. Currently serving as a Senior Scientist for Affimed since April 2021, Jan focuses on tumor models and bispecific antibodies in drug development, overseeing preclinical studies. Previous roles include Strategic Research Scientist and Head of Study Directors at Charles River Laboratories, where Jan managed in vivo studies and led a team in oncology drug development. Jan's extensive background includes project leadership in cell and gene therapy at BioNTech AG, with significant experience in process development and GMP manufacturing. Academic credentials include a PhD in Immunology from FU Berlin and Dana-Farber Cancer Institute and a Master's in Biochemistry from FU Berlin.